ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Can Autoimmune Conditions be Reversed? Researchers Make a Surprising Discovery

How One Tiny Molecule Turned into One Huge Health Breakthrough

Nutrients Boost Stem Cell Function

Humans have three times more brown body fat

B12 Proven Essential for Every Cell

Soy isoflavones may benefit breast cancer patients

How B Vitamins Improve Brain Health, Cognition, Psychiatric Problems and Mood Disorders

Dietary prebiotics improve sleep, buffer impacts of stress, says study

Ylang Ylang Oil Not Only Soothes Your Skin, but Your Mind as Well

Exercises to Help Prevent Urinary Incontinence

 
Print Page
Email Article

Novel Oral Drug for Rheumatoid Arthritis Completes Phase I Clinical Trial

  [ 9 votes ]   [ Discuss This Article ]
www.ProHealth.com • October 26, 2001




AGIX -4207, a novel oral agent being developed for the treatment of rheumatoid arthritis, has completed the escalating single-dose segment of its Phase I clinical trial. This is according to a recent announcement by the drugs manufacturer, AtheroGenics, Inc.

AGIX-4207 is a small molecule drug that represents a unique approach to treating rheumatoid arthritis. Unlike currently marketed biological TNF-alpha (tumor necrosis factor-alpha) inhibitors, AGIX-4207 is a selective modulator of TNF-alpha induced redox-sensitive inflammatory genes. By targeting a specific subset of TNF-alpha activity, it is believed that AGIX-4207 may decrease chronic inflammation in rheumatoid arthritis, while maintaining the body's ability to respond to infection.

The Phase I clinical trial is designed to study the safety, tolerability and pharmacokinetics of single and multiple doses of AGIX-4207 in healthy volunteers. A total of 48 patients in the single-dose segment of the Phase I trial received oral doses of AGIX-4207, ranging from 1mg to 150mg. AGIX-4207 was well tolerated by all patients, and there were no serious adverse events occurring in patients who received the drug. The data have been submitted to the U.S. Food and Drug Administration for review, and a multi-dose segment of the study is expected to be completed by the end of the year.

"We are delighted that AGIX-4207 has successfully completed this first stage of the trial, and we look forward to completing the multi-dosing before the end of this year," said AtheroGenics President and Chief Executive Officer, Russell Medford, M.D., Ph.D. "As we progress through these clinical trial milestones, we remain hopeful that AGIX-4207 might eventually provide those who suffer from rheumatoid arthritis with a safe and effective treatment option for their health and well being."

Rheumatoid arthritis is a chronic and progressively debilitating inflammatory disease that affects more than two million patients in the United States. Approximately 70 percent of those diagnosed with rheumatoid arthritis are young and middle-aged women. Physicians currently treat chronic rheumatoid arthritis in a stepwise fashion, escalating from a regimen of common anti-inflammatory agents like aspirin or ibuprofen, to the use of increasingly toxic drugs that may affect the body's immune system, such as DMARDs (Disease Modifying Anti-Rheumatic Drugs) or biological TNF-alpha inhibitors.



Post a Comment

Featured Products From the ProHealth Store
Energy NADH™ 12.5mg Mitochondria Ignite™ with NT Factor® Ultra EPA  - Fish Oil

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium

Natural Remedies

Block food Cravings At Their Molecular Root Block food Cravings At Their Molecular Root
The Guaifenesin Story: A centuries-old bark extract used for clearing the airways – now key to a popular FM symptom-reversal protocol The Guaifenesin Story: A centuries-old bark extract used for clearing the airways – now key to a popular FM symptom-reversal protocol
Restore Youthful Cognition and Well-Being Restore Youthful Cognition and Well-Being
Coping When Colds or Flu Catch Up with You Coping When Colds or Flu Catch Up with You
Everything You Always Wanted to Know About Sleep But Were Too Tired to Ask Everything You Always Wanted to Know About Sleep But Were Too Tired to Ask

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map